Sorrento Therapeutics Company Profile (NASDAQ:SRNE)

About Sorrento Therapeutics (NASDAQ:SRNE)

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $131.79 million
  • Outstanding Shares: 75,309,000
Average Prices:
  • 50 Day Moving Avg: $1.95
  • 200 Day Moving Avg: $4.34
  • 52 Week Range: $1.55 - $8.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.67
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $12.04 million
  • Price / Sales: 10.95
  • Book Value: $1.33 per share
  • Price / Book: 1.32
Profitability:
  • EBIDTA: ($67,940,000.00)
  • Net Margins: -1,324.35%
  • Return on Equity: -66.87%
  • Return on Assets: -23.45%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 1.99%
  • Quick Ratio: 1.99%
Misc:
  • Average Volume: 832,890 shs.
  • Beta: 1.62
  • Short Ratio: 16.86
 

Frequently Asked Questions for Sorrento Therapeutics (NASDAQ:SRNE)

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics Inc (NASDAQ:SRNE) released its earnings results on Monday, November, 16th. The company reported ($0.03) EPS for the quarter. The company had revenue of $1.10 million for the quarter, compared to analysts' expectations of $1.28 million. Sorrento Therapeutics had a negative return on equity of 66.87% and a negative net margin of 1,324.35%. View Sorrento Therapeutics' Earnings History.

Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2017?

5 brokerages have issued twelve-month target prices for Sorrento Therapeutics' shares. Their predictions range from $9.00 to $20.00. On average, they expect Sorrento Therapeutics' stock price to reach $15.80 in the next year. View Analyst Ratings for Sorrento Therapeutics.

Who are some of Sorrento Therapeutics' key competitors?

Who owns Sorrento Therapeutics stock?

Sorrento Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Wildcat Capital Management LLC (6.46%), Vanguard Group Inc. (3.56%), Intellectus Partners LLC (2.53%), Geode Capital Management LLC (0.85%), Vident Investment Advisory LLC (0.39%) and Bank of America Corp DE (0.35%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, Henry Ji, Jerome B Zeldis, Kevin Herde, Patrick Soon-Shiong and Yue Alexander Wu. View Institutional Ownership Trends for Sorrento Therapeutics.

Who sold Sorrento Therapeutics stock? Who is selling Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Intellectus Partners LLC, Vanguard Group Inc., Wells Fargo & Company MN, TIAA CREF Investment Management LLC, Creative Planning, California Public Employees Retirement System and Bank of New York Mellon Corp. View Insider Buying and Selling for Sorrento Therapeutics.

Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vident Investment Advisory LLC, KCG Holdings Inc., Geode Capital Management LLC and Bank of America Corp DE. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Abg Management Ltd, Henry Ji, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy Sorrento Therapeutics stock?

Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sorrento Therapeutics stock cost?

One share of Sorrento Therapeutics stock can currently be purchased for approximately $1.75.

Analyst Ratings

Consensus Ratings for Sorrento Therapeutics (NASDAQ:SRNE) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.80 (802.86% upside)

Analysts' Ratings History for Sorrento Therapeutics (NASDAQ:SRNE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017HC WainwrightSet Price TargetBuy$20.00HighView Rating Details
5/22/2017Rodman & RenshawLower Price TargetBuy -> Buy$30.00 -> $20.00HighView Rating Details
5/22/2017FBR & CoReiterated RatingOutperform -> Outperform$13.00 -> $9.00HighView Rating Details
11/2/2016Roth CapitalSet Price TargetBuy$15.00N/AView Rating Details
8/12/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
8/3/2015MLV & Co.Initiated CoverageBuy$34.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Sorrento Therapeutics (NASDAQ:SRNE)
Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Earnings History by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$0.08 million$1.28 millionViewN/AView Earnings Details
8/6/2014($0.34)($0.33)$0.08 million$0.78 millionViewN/AView Earnings Details
5/14/2014($0.29)($0.44)$0.12 million$0.98 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)
2017 EPS Consensus Estimate: ($1.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.35)($0.35)($0.35)
Q4 20171($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sorrento Therapeutics (NASDAQ:SRNE)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 25.47%
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Insider Trades by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/19/2017Abg Management LtdMajor ShareholderBuy550,000$2.00$1,100,000.00View SEC Filing  
4/19/2017Henry JiCEOBuy100,000$2.00$200,000.00View SEC Filing  
4/13/2017Abg Management LtdMajor ShareholderBuy2,500,000$2.00$5,000,000.00View SEC Filing  
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.00View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.00View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.00View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.00View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.00View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.92View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.04View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sorrento Therapeutics (NASDAQ:SRNE)
Latest Headlines for Sorrento Therapeutics (NASDAQ:SRNE)
Source:
DateHeadline
americanbankingnews.com logoResearch Analysts Issue Forecasts for Sorrento Therapeutics Inc's Q3 2017 Earnings (SRNE)
www.americanbankingnews.com - May 24 at 8:08 AM
americanbankingnews.com logoHC Wainwright Reiterates "$20.00" Price Target for Sorrento Therapeutics Inc (SRNE)
www.americanbankingnews.com - May 23 at 8:43 PM
americanbankingnews.com logoSorrento Therapeutics Inc (SRNE) PT Lowered to $20.00
www.americanbankingnews.com - May 22 at 8:16 AM
americanbankingnews.com logoFBR & Co Trims Sorrento Therapeutics Inc (SRNE) Target Price to $9.00
www.americanbankingnews.com - May 22 at 8:16 AM
streetinsider.com logoSorrento Therapeutics (SRNE) Announces Completion of GMP Manufacturing Plant in Suzhou, China - StreetInsider.com
www.streetinsider.com - May 4 at 8:41 PM
finance.yahoo.com logoSorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business
finance.yahoo.com - May 4 at 10:51 AM
americanbankingnews.com logoSorrento Therapeutics (SRNE) Earning Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - May 3 at 9:24 PM
bizjournals.com logoOpioid-fighting startup lands CEO, COO with deep pharmaceutical expertise
www.bizjournals.com - May 3 at 6:10 PM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 5:50 PM
prnewswire.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release)
www.prnewswire.com - April 30 at 3:32 PM
prnewswire.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics - PR Newswire (press release)
www.prnewswire.com - April 30 at 3:32 PM
americanbankingnews.com logoSorrento Therapeutics (SRNE) Receiving Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 29 at 8:28 PM
finance.yahoo.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu ... - Yahoo Finance
finance.yahoo.com - April 29 at 2:15 AM
finance.yahoo.com logoSorrento Therapeutics Announces Closing of its Acquisition of Virttu Biologics
finance.yahoo.com - April 28 at 4:13 PM
americanbankingnews.com logoSorrento Therapeutics (SRNE) Earning Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 7:40 PM
americanbankingnews.com logoSorrento Therapeutics Inc (SRNE) Major Shareholder Purchases $1,100,000.00 in Stock
www.americanbankingnews.com - April 21 at 12:27 PM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : April 20, 2017
finance.yahoo.com - April 20 at 8:06 PM
americanbankingnews.com logoInsider Buying: Sorrento Therapeutics Inc (SRNE) CEO Buys 100,000 Shares of Stock
www.americanbankingnews.com - April 19 at 10:45 PM
seekingalpha.com logoSorrento Therapeutics up 9% as CEO adds to stake
seekingalpha.com - April 19 at 7:58 PM
finance.yahoo.com logoSorrento Announces Closing of Public Offering of Common Stock
finance.yahoo.com - April 19 at 7:58 PM
americanbankingnews.com logoSomewhat Negative Media Coverage Very Unlikely to Impact Sorrento Therapeutics (SRNE) Stock Price
www.americanbankingnews.com - April 18 at 3:42 PM
americanbankingnews.com logoInsider Buying: Sorrento Therapeutics Inc (SRNE) Major Shareholder Buys 2,500,000 Shares of Stock
www.americanbankingnews.com - April 18 at 8:23 AM
streetinsider.com logoSorrento Therapeutics (SRNE) Prices 23.63M Common Stock Offering at $2/Share - StreetInsider.com
www.streetinsider.com - April 15 at 6:35 PM
streetinsider.com logoSorrento Therapeutics (SRNE) Plans Offering of Common Stock - StreetInsider.com
www.streetinsider.com - April 14 at 3:43 PM
americanbankingnews.com logoSomewhat Negative Press Coverage Somewhat Likely to Impact Sorrento Therapeutics (SRNE) Stock Price
www.americanbankingnews.com - April 14 at 3:26 PM
finance.yahoo.com logoSorrento Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 13 at 7:48 PM
finance.yahoo.com logoSorrento's stock plunges on heavy volume after stock offering prices at deep discount
finance.yahoo.com - April 13 at 7:48 PM
finance.yahoo.com logoSorrento Therapeutics Gears Up for Secondary Offering
finance.yahoo.com - April 13 at 7:48 PM
finance.yahoo.com logoSorrento Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 12 at 8:13 PM
finance.yahoo.com logoETFs with exposure to Sorrento Therapeutics, Inc. : April 10, 2017
finance.yahoo.com - April 10 at 7:31 PM
americanbankingnews.com logoSorrento Therapeutics Inc (SRNE) Earns Buy Rating from FBR & Co
www.americanbankingnews.com - April 4 at 9:19 PM
streetinsider.com logoSorrento Therapeutics (SRNE) Phase Ib Study of anti-CEA CAR-T Shows Promising Clinical Activity and Safety - StreetInsider.com
www.streetinsider.com - April 4 at 8:27 AM
nasdaq.com logoFDA Nod For TEVA, Cheers For PRTK, SRNE Hits Goal, SNY Launches Kids Toothpaste
www.nasdaq.com - April 4 at 12:45 AM
us.rd.yahoo.com logoSorrento Therapeutics anti-CEA CAR-T Demonstrates Promising Clinical Activity and Safety in Phase Ib Clinical Trial
us.rd.yahoo.com - April 3 at 7:44 PM
americanbankingnews.com logoQ1 2017 EPS Estimates for Sorrento Therapeutics Inc (SRNE) Cut by Analyst
www.americanbankingnews.com - March 27 at 7:14 AM
finance.yahoo.com logoSORRENTO THERAPEUTICS, INC. Financials
finance.yahoo.com - March 25 at 7:35 PM
biz.yahoo.com logoSORRENTO THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 22 at 8:17 AM
biz.yahoo.com logoSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - March 21 at 7:43 PM
us.rd.yahoo.com logo8:14 am Sorrento Therapeutics & Wildcat Capital Management jointly announce that they have reached a mutual understanding and resolution with respect to Wildcat's claims seeking inspection of documents related to the co's private placement
us.rd.yahoo.com - March 20 at 6:04 PM
streetinsider.com logoSorrento Therapeutics (SRNE), Wildcat Announce Resolution of Inspection Demand, Derivative Action - StreetInsider.com
www.streetinsider.com - March 20 at 8:53 AM
finance.yahoo.com logoSorrento and Wildcat Announce Resolution
finance.yahoo.com - March 20 at 8:53 AM
biz.yahoo.com logoSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 20 at 8:53 AM
finance.yahoo.com logoSorrento Therapeutics to Present at 29th Annual ROTH Conference
finance.yahoo.com - March 9 at 7:56 PM
finance.yahoo.com logoInsider Buys Shares of Sorrento Therapeutics
finance.yahoo.com - February 16 at 7:46 PM
finance.yahoo.com logoThe Life Sciences Report Examines the Inclusion of Sorrento Therapeutics on Streetwise Reports' 2017 Small-Cap Biotech Watchlist
finance.yahoo.com - January 23 at 10:13 PM
biz.yahoo.com logoSORRENTO THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
biz.yahoo.com - January 21 at 1:52 AM
streetinsider.com logoSorrento Therapeutics (SRNE) Says Key Endpoints Met in EU Study of ZTlido
www.streetinsider.com - January 9 at 11:38 PM
finance.yahoo.com logoSorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™
finance.yahoo.com - January 9 at 11:38 PM
finance.yahoo.com logo9:01 am Sorrento Therapeutics announces that its pivotal study for its lead investigational product, ZTlido, has met a primary endpoint establishing comparative PK and a secondary endpoint of bioequivalence as compared to the reference prod
finance.yahoo.com - January 9 at 11:38 PM
biz.yahoo.com logoSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclos
biz.yahoo.com - January 6 at 5:20 AM

Social

Chart

Sorrento Therapeutics (SRNE) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff